Recurrent Pregnancy Loss: Summary and Clinical Recommendations

Richard M. Lee; Robert M. Silver

doi:10.1055/s-2000-13733

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2000; 18(4): 433-440
DOI: 10.1055/s-2000-13733

Recurrent Pregnancy Loss: Summary and Clinical Recommendations

Richard M. Lee¹ , Robert M. Silver²

¹Department of Obstetrics & Gynecology, UC Irvine, Orange, California
²Department of Obstetrics & Gynecology, University of Utah, Salt Lake City, Utah

Abstract

ABSTRACT

Recurrent pregnancy loss (RPL) is traditionally defined as three or more consecutive pregnancy losses before 20 weeks of gestation. This problem occurs in approximately 1% of all couples and is a frustrating problem for both the patient and physician. This article provides an overview of the problem, including causes, treatments, and recommendations. Among the numerous proposed causes of RPL, only parental karyotype abnormalities, antiphospholipid syndrome, uterine malformations, and cervical incompetence are universally accepted. There are numerous treatments for RPL, but only the efficacy of heparin and low-dose aspirin in women with antiphospholipid syndrome has been established with properly controlled trials. Even after undertaking a complete evaluation, the cause of RPL remains uncertain in over 50% of cases. These patients should understand that subsequent pregnancies have up to a 70% chance of success without treatment.

KEYWORD

Recurrent pregnancy loss - recurrent miscarriage - habitual abortion

Full Text

References

REFERENCES

1 Coulam C B. Epidemiology of recurrent spontaneous abortion. Am J Reprod Immunol . 1991; 26 23-27
2 Hill J A. Sporadic and recurrent spontaneous abortion. Curr Prob Obstet Gynecol Fertil . 1994; 17 114-162
3 Byrne J LB, Ward K. Genetic factors in recurrent abortion. Clin Obstet Gynecol . 1994; 37 693-704
4 Portnoi M F, Joye N, Van Den Akker J. Karyotypes of 1142 couples with recurrent abortion. Obstet Gynecol . 1988; 72 31-34
5 Simpson J L, Elias S, Martin A O. Parental chromosome rearrangements associated with repetitive spontaneous abortion. Fertil Steril . 1981; 36 584-590
6 ACOG Technical Bulletin Number 212. Early pregnancy loss. September 1995
7 Hassold T J. A cytogenetic study of repeated spontaneous abortions. Am J Hum Genet . 1980; 32 723-730
8 Warburton D, Kline J, Stein Z, Hutzler M, Chin A, Hassold T. Does the karyotype of a spontaneous abortion predict the karyotype of a subsequent abortion?. <~>Evidence from 273 women with two karyotyped spontaneous abortions. Am J Hum Genet . 1987; 41 465-483
9 Byrne J, Warburton D, Kline J, Blanc W, Stein Z. Morphology of early fetal deaths and their chromosomal characteristics. Teratology . 1985; 32 297-315
10 Daya S, Ward S, Burrows E. Progesterone profiles in luteal phase defect cycles and outcome of progesterone treatments in patients with recurrent spontaneous abortion. Am J Obstet Gynecol . 1988; 158 225-232
11 Karamardian L M, Grimes D A. Luteal phase deficiency: effect of treatment on pregnancy rates. Am J Obstet Gynecol . 1992; 167 1391-1398
12 Goldstein P, Berrier J, Rosen S, Sacks H S, Chalmers T C. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol . 1989; 96 265-274
13 Noyes R W, Hertig A TR, Rock J. Dating the endometrial biopsy. Fertil Steril . 1975; 122 262-263
14 Davis O K, Berkeley A S, Naus G J, Cholst I N, Freedman K S. The incidence of luteal phase defect in normal, fertile women, determined by serial endometrial biopsy. Fertil Steril . 1989; 51 582-586
15 Hensleigh P A, Fainstat T. Corpus luteum dysfunction: serum progesterone levels in diagnosis and assessment of therapy for recurrent and threatened abortion. Fertil Steril . 1979; 32 396-400
16 Jordan J, Craig K, Clifton D K, et. al. Luteal phase defect: the sensitivity and specificity of diagnostic methods in common clinical use. Fertil Steril . 1994; 62 54-62
17 Castelbaum A J, Lessey B A. Corpus luteum defect: ``alloyed gold standard'' [letter]. Fertil Steril . 1995; 63 427-428
18 Tulppala M, Bjorses U M, Stenman U H. Luteal phase defect in habitual abortion: progesterone in saliva. Fertil Steril . 1991; 56 41-44
19 Tho P T, Byrd J R, McDonough P G. Etiologies and subsequent reproductive performance of 100 couples with recurrent abortion. Fertil Steril . 1979; 32 389-395
20 Harger J H, Archer D F, Marchese S G, Murracca-Clemens M, Gawer K L. Etiology of recurrent pregnancy loss and outcome of subsequent pregnancies. Obstet Gynecol . 1983; 62 574-581
21 Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol . 1984; 148 140-146
22 Heinonen P K, Saarikoski S, Pystynen P. Reproductive performance of women with uterine anomalies. Acta Obstet Gynaecol Scand . 1982; 61 157-162
23 Musich J R, Behrman S J. Obstetric outcome before and after metroplasty of the septate uterus. J Reprod Med . 1984; 29 185-188
24 Gray S E, Roberts D K, Franklin R R. Fertility after metroplasty of the septate uterus. J Reprod Med . 1984; 29 185-188
25 Buttram V C, Gibbons W E. Müllerian anomalies: a proposed classification (an analysis of 144 cases). Fertil Steril . 1979; 32 40-46
26 Thompson J P, Smith R A, Welch J S. Reproductive ability after metroplasty. Obstet Gynecol . 1966; 28 363-368
27 Capraro V J, Chuang J T, Randall C L. Improved fetal salvage after metroplasty. Obstet Gynecol . 1968; 31 94-103
28 Rock J A, Murphy A A. Anatomic abnormalities. Clin Obstet Gynecol . 1986; 29 886-911
29 Daly D C, Witten C A, Soto-Albers C E, Riddick D H. Hysteroscopic metroplasty: surgical technique and obstetric outcome. Fertil Steril . 1983; 39 623-628
30 March C M, Israel R. Hysteroscopic management of recurrent abortion caused by septate uterus. Am J Obstet Gynecol . 1987; 156 834-839
31 Strassman E O. Fertility and unification of the double uterus. Fertil Steril . 1966; 17 165-176
32 Gros A, David A, Serr D M. Management of congenital malformation of the uterus: fetal salvage. Acta Eur Fertil . 1974; 5 301-304
33 Blum M. Prevention of spontaneous abortion by cervical suture of the malformed uterus. Int Surg . 1977; 62 213-215
34 Golan A, Langer R, Wexler S, Seveg E, Niv D, Menachem P D. Cervical cerclage: its role in the pregnant anomalous uterus. Int J Fertil . 1990; 35 164-170
35 Kaufman R H, Adam E, Binder G L, Gerthoffer E. Upper genital tract changes and pregnancy outcome in offspring exposed in utero to diethylstilbestrol. Am J Obstet Gynecol . 1980; 137 299-308
36 Ludmir J, Landon M B, Gabbe S C, Samuels P, Mennuti M T. Management of the DES-exposed pregnant patient: a prospective study. Am J Obstet Gynecol . 1987; 157 665-669
37 Iams J D, Johnson F F, Sonek J. Cervical competence as a continuum: a study of ultrasonographic cervical length and obstetric performance. Am J Obstet Gynecol . 1995; 172 1097-1106
38 March C M, Israel R. Gestational outcome following hysteroscopic lysis of adhesions. Fertil Steril . 1981; 36 455-459
39 Schenker J G, Margalioth E J. Intrauterine adhesions: an updated appraisal. Fertil Steril . 1982; 37 593-610
40 Stray-Pedersen B, Eng J, Reikvam T M. Uterine T-mycoplasma colonization in reproductive failure. Am J Obstet Gynecol . 1978; 130 307-311
41 Wilson W A, Gharavi A E, Koike T. International consensus statement on preliminary classification criteria for antiphospholipid syndrome: report of an international workshop. Arthritis Rheum . 1999; 42 1309-1311
42 Silver R M, Porter T F, van Leeuwen I, Jeng G, Scott J R, Branch D W. Anticardiolipin antibodies: clinical consequences of ``low titers''. Obstet Gynecol . 1996; 87 494-500
43 Branch D W, Silver R M, Pierangelli S S, van Leeuwen I, Harris E N. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol . 1997; 89 549-555
44 Oshiro B T, Silver R M, Scott J R, Yu H, Branch D W. Antiphospholipid antibodies and fetal death. Obstet Gynecol . 1996; 87 489-493
45 Branch D W, Scott J R. Clinical implications of anti-phospholipid antibodies: the Utah experience. In: Harris EN, Exner T, Hughes GRV, Asherson RA, eds. Phospholipid-Binding Antibodies Boca Raton, FL: CRC Press 1991: 335-346
46 Out H J, Bruinse H W, Christianens G M L C. Prevalence of antiphospholipid antibodies in patients with fetal loss. Ann Rheum Dis . 1991; 50 553-557
47 Parazzini F, Acaia B, Faden D, Lovotti M, Marelli G, Cortelazzo S. Antiphospholipid antibodies and recurrent abortion. Obstet Gynecol . 1991; 77 854-858
48 Parke A L, Wilson D, Maier D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum . 1991; 34 1231-1235
49 Branch D W, Silver R M, Blackwell J L, Reading J C, Scott J R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol . 1992; 80 614-620
50 Rosove M H, Tabsh K, Wasserstrum N, Howard P, Hahn B H, Kalunian K C. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol . 1990; 75 630-634
51 Cowchock F S, Reece E A, Balaban D. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone to low-dose heparin treatment. Am J Obstet Gynecol . 1992; 166 1318-1323
52 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnancy in women with recurrent miscarriage associated with phospholipid antibodies. BMJ . 1997; 314 253-257
53 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol . 1996; 35 1584-1589
54 Clark A L, Branch D W, Silver R M, Harris E N, Pierangeli S, Spinnato J A. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet Gynecol . 1999; 93 437-441
55 Branch D W, Peaceman A M, Druzin M. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol . 2000; 182 122-127
56 Preston F E, Rosendaal F R, Walker I D. Increased fetal loss in women with heritable thrombophilia. Lancet . 1996; 348 913-916
57 Wouters M G, Boers G H, Blom H J. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril . 1993; 60 820-825
58 Schved J F, Gris J C, Neveu S. Factor XII congenital deficiency and early spontaneous abortion. Fertil Steril . 1989; 52 335-336
59 Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism. N Engl J Med . 1994; 330 517-522
60 Bertina R M, Koeleman B P, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-67
61 Branch D W. Immunologic aspects of pregnancy loss: alloimmune and autoimmune considerations. In: Reece EA, Hobbins JC, Mahoney MJ, Petrie RH, eds. Medicine of the Fetus and Mother Philadelphia: JB Lippincott 1992: 217-233
62 Kutteh W H, Stovall D W, Scott J R. The immunologic diagnosis and treatment of recurrent pregnancy loss. Infertil Reprod Med Clin North Am . 1997; 8 267-287
63 Coulam C B, Clark D A, Collins J, Scott J R. Worldwide collaborative observational study and meta-analysis on allogeneic leukocyte immunotherapy for recurrent spontaneous abortion. Am J Reprod Immunol . 1994; 23 55-72
64 Jeng G T, Scott J R, Burmeister L F. A comparison of meta-analytic results using literature versus individual patient data. JAMA . 1995; 274 830-836
65 Ober C, Karrison T, Odem R R. Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. Lancet . 1999; 354 365-369
66 Coulam C B, Krysa L, Stern J J, Bustillo M. Intravenous immunoglobulin for the treatment of recurrent pregnancy loss. Am J Reprod Immunol . 1995; 34 333-338
67 The German RSA/IVIG Group. Intravenous immune globulin in the prevention of recurrent miscarriage. Br J Obstet Gynaecol . 1994; 101 1072-1077
68 Christiansen O B, Mathiesen O, Husth M. Placebo controlled trial for treatment of unexplained secondary recurrent abortions and recurrent late spontaneous abortions with iv immunoglobulin. Hum Reprod . 1995; 10 2690-2694
69 Mowbray S F, Gibbons C, Liddell H. Controlled trial of treatment of recurrent spontaneous abortion by immunization with paternal cells. Lancet . 1985; 1 941-943
70 Ho H N, Gill T H, Hsieh H J, Jiang J J, Lee T Y, Hsieh C Y. Immunotherapy for recurrent spontaneous abortions in a Chinese population. Am J Reprod Immunol . 1991; 25 10-15
71 Tupper C, Weil R J. The problem of spontaneous abortion. Am J Obstet Gynecol . 1962; 83 421-429
72 Stray-Pedersen B, Stray-Pedersen S. Recurrent abortion: the role of psychotherapy. In: Beard RW, Sharp F, eds. Early Pregnancy Loss London: Springer-Verlag 1988: 433-440